|
04 Dec 2019 |
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
|
|
04 Dec 2019 |
Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
|
|
04 Dec 2019 |
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
|
|
04 Dec 2019 |
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer
|
|
04 Dec 2019 |
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
|
|
04 Dec 2019 |
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
|
|
04 Dec 2019 |
Censa Pharmaceuticals Announces CNSA-001 Met Primary and Secondary Endpoints in Phase 2 Trial in Patients with PKU
|
|
04 Dec 2019 |
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications
|
|
04 Dec 2019 |
Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe
|
|
04 Dec 2019 |
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
|
|
04 Dec 2019 |
Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
|
|
04 Dec 2019 |
FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
|
|
03 Dec 2019 |
Announcement of Joint Development Agreement of Aflibercept Biosimilars with Kishi Kasei Co., Ltd.
|
|
03 Dec 2019 |
IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets
|
|
03 Dec 2019 |
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
|
|
03 Dec 2019 |
OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
|
|
03 Dec 2019 |
Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone
|
|
03 Dec 2019 |
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
|
|
03 Dec 2019 |
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
|
|
03 Dec 2019 |
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
|
